Früh M - Search Results

1

Epidermal growth factor receptor and anaplastic lymphoma kinase testing and mutation prevalence in patients with advanced non-small cell lung cancer in Switzerland: A comprehensive evaluation of real world practices.

Ess SM, Herrmann C, Frick H, Krapf M, Cerny T, Jochum W, Früh M. Ess SM, et al. Among authors: fruh m. Eur J Cancer Care (Engl). 2017 Nov;26(6). doi: 10.1111/ecc.12721. Epub 2017 May 30. Eur J Cancer Care (Engl). 2017. PMID: 28557060

2

Management of elderly patients with advanced non-small cell lung cancer: a single-center experience.

Früh M, Besrour H, Gillessen S, Joerger M, Hitz F, Savidan A, Cerny T, Ess S. Früh M, et al. Chemotherapy. 2013;59(1):42-50. doi: 10.1159/000350498. Epub 2013 Jul 2. Chemotherapy. 2013. PMID: 23838903

3

Diffuse large B-cell lymphoma in elderly patients: a retrospective analysis.

Diem S, Ess S, Cerny T, Früh M, Hitz F. Diem S, et al. Among authors: fruh m. Eur J Intern Med. 2014 Jul;25(6):577-82. doi: 10.1016/j.ejim.2014.05.001. Epub 2014 May 28. Eur J Intern Med. 2014. PMID: 24881010

4

Erlotinib has comparable clinical efficacy to chemotherapy in pretreated patients with advanced non-small cell lung cancer (NSCLC): A propensity-adjusted, outcomes research-based study.

Neumair P, Joos L, Warschkow R, Dutly A, Ess S, Hitz F, Früh M, Brutsche M, Baty F, Krähenbühl S, Cerny T, Joerger M. Neumair P, et al. Among authors: fruh m. Lung Cancer. 2016 Oct;100:38-44. doi: 10.1016/j.lungcan.2016.07.027. Epub 2016 Jul 28. Lung Cancer. 2016. PMID: 27597279

5

Two-weekly gemcitabine fixed dose rate and oxaliplatin combination chemotherapy for advanced non-small-cell lung cancer.

Früh M, Gillessen S, Cerny T, Demmer R, D'Addario G. Früh M, et al. Lung Cancer. 2008 Dec;62(3):344-50. doi: 10.1016/j.lungcan.2008.03.028. Epub 2008 May 15. Lung Cancer. 2008. PMID: 18485522 Clinical Trial.

6

The role of pemetrexed in advanced non small-cell lung cancer: special focus on pharmacology and mechanism of action.

Joerger M, Omlin A, Cerny T, Früh M. Joerger M, et al. Among authors: fruh m. Curr Drug Targets. 2010 Jan;11(1):37-47. doi: 10.2174/138945010790030974. Curr Drug Targets. 2010. PMID: 19839929 Review.

7

Patterns of progression on osimertinib in EGFR T790M positive NSCLC: A Swiss cohort study.

Schmid S, Klingbiel D, Aeppli S, Britschgi C, Gautschi O, Pless M, Rothschild S, Wannesson L, Janthur W, Foerbs D, Demmer I, Jochum W, Früh M. Schmid S, et al. Among authors: fruh m. Lung Cancer. 2019 Apr;130:149-155. doi: 10.1016/j.lungcan.2019.02.020. Epub 2019 Feb 19. Lung Cancer. 2019. PMID: 30885336

8

Activity of pemetrexed against brain metastases in a patient with adenocarcinoma of the lung.

Omlin A, D'Addario G, Gillessen S, Cerny T, von Hessling A, Früh M. Omlin A, et al. Among authors: fruh m. Lung Cancer. 2009 Sep;65(3):383-4. doi: 10.1016/j.lungcan.2009.03.019. Epub 2009 Apr 17. Lung Cancer. 2009. PMID: 19375814

9

EGFR mutation subtype impacts efficacy of immune checkpoint inhibitors in non-small-cell lung cancer.

Früh M, Peters S. Früh M, et al. Ann Oncol. 2019 Aug 1;30(8):1190-1192. doi: 10.1093/annonc/mdz185. Ann Oncol. 2019. PMID: 31198952 Free article. No abstract available.

10

Addition of cetuximab to first-line chemotherapy in patients with advanced non-small-cell lung cancer: a cost-utility analysis.

Joerger M, Matter-Walstra K, Früh M, Kühnel U, Szucs T, Pestalozzi B, Schwenkglenks M. Joerger M, et al. Among authors: fruh m. Ann Oncol. 2011 Mar;22(3):567-574. doi: 10.1093/annonc/mdq431. Epub 2010 Sep 13. Ann Oncol. 2011. PMID: 20843984 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

139 results

Search Page

Filters